Shares of GeneDx Holdings Corp. (WGS) experienced a dramatic decline on Tuesday, plunging approximately 51% to $33.12 after the genetic testing company significantly lowered its 2026 revenue forecast. The sharp selloff erased more than $1 billion in market capitalization, bringing the Stamford, Connecticut-based company's valuation to roughly $970 million. The drop was company-specific, far exceeding losses at peers like Natera, Guardant Health, and Illumina.
Revenue Guidance Slashed
GeneDx reduced its full-year 2026 revenue guidance to a range of $475 million to $490 million, well below the previous forecast of $540 million to $555 million. The company also scaled back its expectations for exome and genome revenue growth, now projecting at least 20%, down from the earlier 33% to 35% view. Chief Financial Officer Kevin Feeley admitted the original outlook was 'too aggressive,' attributing the misstep to an unexpectedly fast shift in product mix and overestimated contributions from new markets.
First-Quarter Results Miss
For the first quarter, GeneDx reported revenue of $102.3 million, a 17% year-over-year increase, but this fell short of analyst expectations. Exome and genome test revenue rose 27% to $90.6 million, with test volume jumping 34% to 27,488. Despite the volume growth, the company posted an adjusted net loss of $8.2 million and a GAAP net loss of $63.3 million. Management maintained its target for positive adjusted net income this year, but analysts are questioning the credibility of that goal.
Reimbursement Challenges
The primary headwind was reimbursement. GeneDx reported a blended average reimbursement rate of approximately $3,300 per test, about $200 below projections. Outpatient genome testing, which made up close to 40% of first-quarter outpatient volume, carried reimbursement rates roughly half those of exome tests, reflecting lagging payer coverage. Feeley noted that improving outpatient genome reimbursement could take years.
Analyst Reactions
Wall Street responded swiftly. Canaccord Genuity analyst Kyle Mikson described the results as 'alarming,' lowering his price target to $75 from $100 while maintaining a buy rating. Freedom Capital Markets' Keith Hinton slashed his target to $93 from $177, citing shaky management credibility and warning GeneDx could remain 'in the penalty box' until leadership regains trust. Wells Fargo cut its target to $75 from $155 but kept an Overweight rating, noting that exome and genome volumes held up well.
Balance Sheet Concerns
The selloff also reflects worries about the company's financial health. GeneDx disclosed an $11.9 million non-cash goodwill impairment related to Fabric Genomics, along with additional impairment charges on intangible assets. The company took out a $100 million term loan from Blackstone in February and reported a $6.6 million loss from retiring earlier debt. As of March 31, cash and marketable securities totaled $171.7 million. Another guidance miss could intensify scrutiny on cash management and the timeline to adjusted profitability.
Cost-Cutting Measures
Management announced plans to cut $25 million in operating expenses, primarily through reduced hiring and marketing, while preserving key growth initiatives. For the second quarter, GeneDx expects revenue between $110 million and $112 million, approximately 30,000 exome and genome tests, and an adjusted net loss of around $5 million. The company insists competitive dynamics remain unchanged, but investors are now focused on whether it can close the reimbursement gap and ramp up volumes fast enough to deliver the promised scale.
